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Belimumab and the measurement of fatigue
I read with great interest the article by Strand et al.1 The aim of
the study was to assess the effects of belimumab treatment plus
standard systemic lupus erythematosus (SLE) therapy on
health-related quality of life in patients with active,
autoantibody-positive SLE. Of particular interest are the results
about the impact of belimumab on fatigue scores.
Fatigue is a common complaint of patients with SLE and is
associated with diminished ability to function.2 3 In the majority
of cases, the cause of fatigue is still unexplained and it is likely
that many factors together lead to lupus fatigue.2 However,
until recently, clinical trials have not routinely assessed fatigue.3
The article by Strand et al1 showed that belimumab treatment
can partially reduce fatigue, measured through the Functional
Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F
scale).4 In more detail, FACIT-F scores were not significantly dif-
ferent across treatment groups at the week 24 prespecified sec-
ondary endpoint. However, scores from baseline to week 52
improved significantly (p<0.05) with belimumab 1 and 10 mg/kg
versus placebo in A Study of Belimumab in Subjects with
Systemic Lupus Erythematosus (BLISS)-52, and with 1 mg/kg at
weeks 52 and 76 secondary endpoints in BLISS-76. Differences
observed between belimumab 10 mg/kg and placebo were not
statistically significant in BLISS-76, but numerical improvements
over placebo were observed by week 8 and sustained through
week 76.1
The BLISS trials adopted the FACIT-F as one of the outcome
measures. This scale is a 13-item questionnaire that assesses self-
reported fatigue and its effect upon daily activities and function.
It was originally developed for the precise evaluation of fatigue
associated with anaemia in patients with cancer. Subsequently, it
has been employed in many diseases, including patients with
rheumatoid arthritis4 and psoriatic arthritis.5
FACIT-F is usually considered a unidimensional scale, with
high internal reliability. However, in a recent study, published
after the design of BLISS trials, the factorial structure of the
FACIT-F has been questioned. More precisely, in the work by
Cella et al,6 the 13 items were classified into either ‘experience’
(five items) or ‘impact’ (eight items). Experience items inquire
about perceptions and severity of feeling states, including tired-
ness, energy level, weakness, fatigue and listlessness. Impact
items inquire as to whether fatigue (or tiredness) has had an
impact upon an individual’s daily functioning such as perform-
ing usual activities, social activity, sleep and eating. Item
classification was done independently by three investigators with
100% agreement, and these classifications were confirmed in
subsequent meetings with external groups including investiga-
tors from the pharmaceutical industry and the US Food and
Drug Administration. Moreover, experience scores, while highly
correlated to impact scores, appeared to be systematically lower
(worse) than impact scores, across the samples. The authors con-
cluded that, even if it is valid to report a single score, according
to bifactor analysis, it would be valid if clinicians decide to
report experience and impact scores separately.6 What I wonder
here is whether Strand et al considered the opportunity to run
analyses, separating these two fatigue dimensions. Moreover, I
suggest that a further investigation on smaller groups of items
(or single items), even if explorative and not strictly informative
for treatment efficacy, would lead to a better understanding of
the treatment effects. These results would be inspiring for both
future research on belimumab and for the physiological and psy-
chological processes that may contribute to fatigue during the
course of SLE.
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